Target product profiles for small molecule or engineered antibody therapeutics for treatment of snakebite envenoming

The first WHO public-benefit Target Product Profiles (TPPs) for the treatment of snakebites using novel therapeutics. The objective of these TPPs is to provide researchers, regulators and manufacturers with essential information about the minimum and optimum characteristics of potential treatments for snakebites, whether small molecule drugs or engineered antibody biologics. Our aim in doing this is to generate a set of guidelines for products in development, to ensure that they are designed and manufactured to match the clinical needs of populations at risk, and are both safe and effective.